<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0">
    <channel>
      <title>SignalTrace</title>
      <link>https://www.signaltrace.wiki/tirzepatide</link>
      <description>Last 10 notes on SignalTrace</description>
      <generator>Quartz -- quartz.jzhao.xyz</generator>
      <item>
    <title>Albuminuria</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Albuminuria</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Albuminuria</guid>
    <description><![CDATA[ Albuminuria Albuminuria — measured as urine albumin-to-creatinine ratio (UACR, mg/g) — is a biomarker of glomerular damage and an independent predictor of CKD progression and cardiovascular risk. ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item><item>
    <title>Cardiovascular Risk</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Cardiovascular-Risk</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Cardiovascular-Risk</guid>
    <description><![CDATA[ Cardiovascular Risk Tirzepatide’s cardiovascular outcomes are now established through SURPASS-CVOT (NEJM 2025), a dedicated cardiovascular outcomes trial comparing tirzepatide vs dulaglutide in 13,299 adults with T2D and established ASCVD, followed for a median of 4 years. ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item><item>
    <title>Circulation Claims</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Circulation-Claims</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Circulation-Claims</guid>
    <description><![CDATA[ Circulation Claims The claim that tirzepatide “improves blood circulation” is a common marketing assertion that lacks direct clinical evidence. ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item><item>
    <title>HbA1c Reduction</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/HbA1c-Reduction</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/HbA1c-Reduction</guid>
    <description><![CDATA[ HbA1c Reduction HbA1c (glycated haemoglobin) is the primary clinical measure of long-term blood sugar control in Type 2 diabetes. ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item><item>
    <title>Heart Failure Outcomes</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Heart-Failure-Outcomes</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Heart-Failure-Outcomes</guid>
    <description><![CDATA[ Heart Failure Outcomes The SUMMIT trial (presented at AHA 2024, simultaneously published in NEJM) evaluated tirzepatide in 731 patients with obesity-related heart failure with preserved ejection fraction (HFpEF) over approximately 2 years. ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item><item>
    <title>Insulin-Use Reduction</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Insulin-Use-Reduction</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Insulin-Use-Reduction</guid>
    <description><![CDATA[ Insulin-Use Reduction Tirzepatide’s relationship to insulin use must be understood in two distinct contexts: (1) as an alternative to insulin initiation in patients not yet on injectable therapy, and (2) as a replacement for or complement to insulin regimes in patients already using basal insulin. ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item><item>
    <title>Kidney Outcomes</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Kidney-Outcomes</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Kidney-Outcomes</guid>
    <description><![CDATA[ Kidney Outcomes Evidence for tirzepatide’s effects on kidney function comes from post-hoc analyses of the SURPASS programme and secondary outcomes of the SURMOUNT obesity trials — not from a dedicated, powered kidney outcome trial. ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item><item>
    <title>MASLD NAFLD Outcomes</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/MASLD-NAFLD-Outcomes</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/MASLD-NAFLD-Outcomes</guid>
    <description><![CDATA[ MASLD and NAFLD Liver Outcomes Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is a major comorbidity of T2D — approximately 25–30% of T2D adults have some degree of MASLD, and a subset progress to metabolic-associated steatohepatitis (MASH, formerly NASH), which car... ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item><item>
    <title>Real-World Evidence T2D</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Real-World-Evidence-T2D</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Real-World-Evidence-T2D</guid>
    <description><![CDATA[ Real-World Evidence T2D Post-approval real-world evidence (RWE) is critical for confirming that RCT benefits replicate in clinical practice, particularly in patient populations excluded from trials (older adults, multiple comorbidities, lower socioeconomic status). ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item><item>
    <title>Weight Loss in T2D</title>
    <link>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Weight-Loss-in-T2D</link>
    <guid>https://www.signaltrace.wiki/tirzepatide/ClinicalOutcomes/Weight-Loss-in-T2D</guid>
    <description><![CDATA[ Weight Loss in T2D Tirzepatide produces dose-dependent weight loss in T2D trials: −7.0 to −9.5 kg (SURPASS-1, monotherapy vs placebo), −8.0 to −14.0 kg in later trials. ]]></description>
    <pubDate>Sun, 10 May 2026 16:53:33 GMT</pubDate>
  </item>
    </channel>
  </rss>